Tag: Diabetes: Drugs
Medication Type for T2DM May Affect Severe COVID-19 Outcomes
Premorbid GLP1-RA use, SGLT2i use associated with lower 60-day mortality compared to premorbid DPP4i use
Study Looks at T2DM, Metformin Use, and Breast Cancer Risk
Links between T2DM with metformin use and breast cancer risk appear to be affected by hormone receptor status
Metformin Use May Reduce Mortality in Women With COVID-19
In overall sample of men and women, metformin use was not linked to significantly reduced mortality
Use of Common Meds Tied to Lower Lung Cancer Mortality
Combined use of aspirin, statins, metformin tied to lower lung cancer risk and mortality
Metformin Recalled Due to Potential Cancer-Causing Chemical
Recall is for all lots of metformin hydrochloride extended-release tablets 500 mg from Apotex
FDA: Insulin Among Drugs Transitioned to Biological Products
New regulatory pathway for biologic drugs allows for approval of biosimilars, interchangeable versions
SGLT-2 Inhibitor Use Not Linked to Increased Risk for UTI Events
Findings seen in propensity-matched cohorts versus receipt of DPP-4 inhibitors or GLP-1 agonists
Metformin May Cut Mortality Risk in Post-Pancreatitis Diabetes
Survival benefit not seen with ever use of metformin for pancreatic cancer-related diabetes
Second-Line Antidiabetic Meds May Impact Cardiovascular Risk
Cardiovascular risk increased with sulfonylureas and basal insulin versus newer classes of ADM
DPP-4I Not Tied to Increased Risk of Acute Pancreatitis in Seniors
Among adults with heart disease, risk increased with DPP-4I versus thiazolidinedione not sulfonylureas
